18 F-flutemetamol positron emission tomography in cardiac amyloidosis
- PDF / 1,355,498 Bytes
- 11 Pages / 593.972 x 792 pts Page_size
- 25 Downloads / 212 Views
F-flutemetamol positron emission tomography in cardiac amyloidosis Maria Papathanasiou, MD,a Lukas Kessler, MD,b Alexander Carpinteiro, MD,c,d Tim Hagenacker, MD,e Felix Nensa, MD,f Lale Umutlu, MD,f Michael Forsting, MD,f Alexandra Brainman, MD,b Christoph Kleinschnitz, MD,e Gerald Antoch, MD,g ¨ hrsen, MD,c Thomas-Wilfried Schlosser, MD,f Ken Herrmann, MD,b Ulrich Du Tienush Rassaf, MD,a Peter Luedike, MD,a and Christoph Rischpler, MDb a
b c
d e f
g
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany Department of Nuclear Medicine, University Hospital Essen, Essen, Germany Department of Hematology, West German Tumor Center, University Hospital Essen, Essen, Germany Department of Molecular Biology, University of Duisburg-Essen, Essen, Germany Department of Neurology, University Hospital Essen, Essen, Germany Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany Department of Diagnostic and Interventional Radiology, University Hospital Duesseldorf, Duesseldorf, Germany
Received Jul 5, 2020; accepted Aug 12, 2020 doi:10.1007/s12350-020-02363-2
Purpose. Bone-tracer scintigraphy has an established role in diagnosis of cardiac amyloidosis (CA) as it detects transthyretin amyloidosis (ATTR). Positron emission tomography (PET) with amyloid tracers has shown high sensitivity for detection of both ATTR and lightchain (AL) CA. We aimed to investigate the accuracy of 18F-flutemetamol in CA. Methods. We enrolled patients with CA or non-amyloid heart failure (NA-HF), who underwent cardiac 18F-flutemetamol PET/MRI or PET/CT. Myocardial and blood pool standardized tracer uptake values (SUV) were estimated. Late gadolinium enhancement (LGE) and T1 mapping/ extracellular volume (ECV) estimation were performed. Results. We included 17 patients (12 with CA, 5 with NA-HF). PET/MRI was conducted in 13 patients, while PET/CT was conducted in 4. LGE was detected in 8 of 9 CA patients. Global relaxation time and ECV were higher in CA (1448 vs. 1326, P = 0.02 and 58.9 vs. 33.7%, P = 0.006, respectively). Positive PET studies were demonstrated in 2 of 12 patients with CA (AL and ATTR). Maximal and mean SUV did not differ between groups (2.21 vs. 1.69, P = 0.18 and 1.73 vs. 1.30, P = 0.13). Maria Papathanasiou and Lukas Kessler first authors contributed equally to this work. Peter Luedike and Christoph Rischpler senior authors contributed equally to this work. Electronic supplementary material The online version of this article (doi:https://doi.org/10.1007/s12350-020-02363-2) contains supplementary material, which is available to authorized users.
Reprint requests: Maria Papathanasiou, MD, Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany; [email protected] 1071-3581/$34.00 Copyright Ó 2020 The Author(s)
Papathanasiou et al 18 F-flutemetamol PET in cardiac amyloidosis
Journal o
Data Loading...
